- Home
- ZLAB vs PTCT Comparison
ZLAB vs PTCT Comparison
Compare ZLAB & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- PTCT
- Stock Information
- Founded
- ZLAB 2013
- PTCT 1998
- Country
- ZLAB China
- PTCT United States
- Employees
- ZLAB N/A
- PTCT N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- ZLAB Health Care
- PTCT Health Care
- Exchange
- ZLAB Nasdaq
- PTCT Nasdaq
- Market Cap
- ZLAB 3.0B
- PTCT 3.1B
- IPO Year
- ZLAB 2017
- PTCT 2013
- Fundamental
- Price
- ZLAB $26.67
- PTCT $42.96
- Analyst Decision
- ZLAB Strong Buy
- PTCT Hold
- Analyst Count
- ZLAB 4
- PTCT 12
- Target Price
- ZLAB $52.50
- PTCT $41.83
- AVG Volume (30 Days)
- ZLAB 1.1M
- PTCT 737.4K
- Earning Date
- ZLAB 11-12-2024
- PTCT 11-07-2024
- Dividend Yield
- ZLAB N/A
- PTCT N/A
- EPS Growth
- ZLAB N/A
- PTCT N/A
- EPS
- ZLAB N/A
- PTCT N/A
- Revenue
- ZLAB $355,748,000.00
- PTCT $900,664,000.00
- Revenue This Year
- ZLAB $48.50
- PTCT N/A
- Revenue Next Year
- ZLAB $47.37
- PTCT N/A
- P/E Ratio
- ZLAB N/A
- PTCT N/A
- Revenue Growth
- ZLAB 35.01
- PTCT 12.84
- 52 Week Low
- ZLAB $13.48
- PTCT $19.75
- 52 Week High
- ZLAB $36.60
- PTCT $46.98
- Technical
- Relative Strength Index (RSI)
- ZLAB 41.98
- PTCT 63.43
- Support Level
- ZLAB $27.74
- PTCT $43.48
- Resistance Level
- ZLAB $32.15
- PTCT $46.98
- Average True Range (ATR)
- ZLAB 1.36
- PTCT 1.79
- MACD
- ZLAB -0.64
- PTCT 0.23
- Stochastic Oscillator
- ZLAB 3.15
- PTCT 61.03
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.